Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects
Open Access
- 19 January 2022
- Vol. 11 (3), 320
- https://doi.org/10.3390/cells11030320
Abstract
Non-small cell lung cancer is one of the most common types of malignances worldwide and the main cause of cancer-related deaths. Current treatment for NSCLC is based on surgical resection, chemotherapy, radiotherapy, and targeted therapy, with poor therapeutic effectiveness. In recent years, immune checkpoint inhibitors have applied in NSCLC treatment. A large number of experimental studies have shown that immune checkpoint inhibitors are safer and more effective than traditional therapeutic modalities and have allowed for the development of better guidance in the clinical treatment of advanced NSCLC patients. In this review, we describe clinical trials using ICI immunotherapies for NSCLC treatment, the available data on clinical efficacy, and the emerging evidence regarding biomarkers.Keywords
This publication has 131 references indexed in Scilit:
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patientsNature, 2014
- Nivolumab: A Review of Its Use in Patients with Malignant MelanomaDrugs, 2014
- Radiation-induced survival responses promote immunogenic modulation to enhance immunotherapy in combinatorial regimensOncoImmunology, 2014
- Targeting PD-1/PD-L1 interactions for cancer immunotherapyOncoImmunology, 2012
- Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancerCancer Immunology, Immunotherapy, 2012
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- Enhanced Tumor Eradication by Combining CTLA-4 or PD-1 Blockade With CpG TherapyJournal of Immunotherapy, 2010
- CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct MechanismsMolecular and Cellular Biology, 2005
- Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasionNature Medicine, 2002
- Tumor Angiogenesis: Therapeutic ImplicationsThe New England Journal of Medicine, 1971